Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2011 Feb 15;21(4):1141-5. doi: 10.1016/j.bmcl.2010.12.109. Epub 2010 Dec 28.

Spirodiketopiperazine-based CCR5 antagonist: discovery of an antiretroviral drug candidate.

Author information

  • 1Medicinal Chemistry Research Laboratory, Ono Pharmaceutical Co., Ltd, Shimamoto, Mishima, Osaka 618-8585, Japan. r.nishizawa@ono.co.jp

Abstract

Following the discovery that hydroxylated derivative 3 (Fig. 1) was one of the oxidative metabolites of the original lead 1, it was found that hydroxylated compound 4 possesses higher in vitro anti-HIV potency than the corresponding non-hydroxylated compound 2. Structural hybridation of 4 with the orally available analog 5 resulted in another orally-available spirodiketopiperazine CCR5 antagonist 6a that possesses more favorable pharmaceutical profile for use as a drug candidate.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID:
21256008
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk